Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Primary care diabetes"
DOI: 10.1016/j.pcd.2020.08.012
Abstract: AIM The effects of dipeptidyl peptide-4 inhibitors (DPP-4is) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) on type 2 diabetes mellitus (T2DM) on cardiovascular events and all-cause mortality were compared. METHODS The literature on DPP-4is and SGLT-2is treatment… read more here.
Keywords: peptide; dpp 4is; mortality; sglt 2is ... See more keywords
The safety of gliptins : updated data in 2018
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2018.1444027
Abstract: ABSTRACT Introduction: Dipeptidyl peptidase-4 inhibitors (DPP-4is) are generally considered as glucose-lowering agents with a safe profile in type 2 diabetes. Areas covered: An updated review of recent safety data from randomised controlled trials, observational studies,… read more here.
Keywords: gliptins updated; dpp 4is; safety; safety gliptins ... See more keywords
Bullous Pemphigoid in Patients with Non-small-cell Lung Cancer Complicated by Diabetes Mellitus Receiving Dipeptidyl Peptidase-4 Inhibitors and Immune Checkpoint Inhibitors: A Case Report of Two Patients and Review of Literature
Sign Up to like & getrecommendations! Published in 2025 at "Internal Medicine"
DOI: 10.2169/internalmedicine.5090-24
Abstract: Dipeptidyl peptidase-4 inhibitors (DPP-4is) are shown to be associated with the development of bullous pemphigoid (BP). Immune checkpoint inhibitors (ICIs) can lead to BP development. Therefore, the combination of DPP-4is and ICIs may predispose an… read more here.
Keywords: peptidase inhibitors; dipeptidyl peptidase; immune checkpoint; bullous pemphigoid ... See more keywords
2338-PUB: Metformin Administration Attenuates Dipeptidyl Peptidase-4 Inhibitor-Induced KL-6 Level Elevation
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-2338-pub
Abstract: Given the lack of clarity regarding the benefits of metformin in patients with type 2 diabetes mellitus who were prescribed DPP-4 inhibitors (DPP-4is), we compared KL-6 levels in patients who were prescribed DPP-4is and in… read more here.
Keywords: patients prescribed; none; prescribed dpp; pub metformin ... See more keywords
Comparing ischemic cardiovascular effectiveness and safety between individual SGLT-2 inhibitors and DPP-4 inhibitors in patients with type 2 diabetes: a nationwide population-based cohort study
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2024.1443175
Abstract: Objectives This study compared the ischemic cardiovascular events (iCVEs) effectiveness and safety of initiating empagliflozin or dapagliflozin with those of dipeptidyl peptidase-4 inhibitors (DPP-4is), as well as the comparative effects between empagliflozin and dapagliflozin. Methods… read more here.
Keywords: empagliflozin dapagliflozin; effectiveness safety; ischemic cardiovascular; safety ... See more keywords
Gemigliptin Alleviates Succinate-Induced Hepatic Stellate Cell Activation by Ameliorating Mitochondrial Dysfunction
Sign Up to like & getrecommendations! Published in 2022 at "Endocrinology and Metabolism"
DOI: 10.3803/enm.2022.1530
Abstract: Background Dipeptidyl peptidase-4 inhibitors (DPP-4Is) are used clinically as oral antidiabetic agents. Although DPP-4Is are known to ameliorate liver fibrosis, the protective mechanism of DPP-4Is in liver fibrosis remains obscure. In this study, gemigliptin was… read more here.
Keywords: mitochondrial dysfunction; dpp 4is; liver fibrosis; gemigliptin ... See more keywords
Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "World Journal of Diabetes"
DOI: 10.4239/wjd.v13.i6.466
Abstract: SGLT-2 inhibitors (SGLT-2Is) have significantly improved cardio-renal outcomes and are preferred agents in people with cardiovascular diseases, heart failure, and diabetic kidney disease. Similarly, GLP-1 receptor agonists (GLP-1RAs) have significantly improved atherosclerotic cardiovascular outcomes. To… read more here.
Keywords: sglt 2is; dpp 4is; sglt inhibitors; hba1c ... See more keywords